We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) to Buy Mobidiag, Boost Diagnostics Testing Arm
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) recently entered into a definitive agreement to acquire Finnish-French biotechnology company Mobidiag Oy for an enterprise value of nearly $795 million. This development is likely to strengthen Hologic’s diagnostics business and accelerate growth post-COVID.
Notably, the transaction is anticipated to close early in the fourth quarter of fiscal 2021, subject to the receipt of certain regulatory approvals and other customary closing conditions.
Financial Terms of the Deal
The transaction includes a cash payment of nearly $714 million for Mobidiag’s equity and net debt of around $81 million.
For investors’ note, Mobidiag generated revenues of $42 million (€35 million) in 2020.
Hologic expects the acquisition to prove dilutive to its adjusted earnings per share by around 10 cents in fiscal 2022, slightly dilutive in 2023, accretive thereafter.
Mobidiag at a Glance
Mobidiag is a developer and marketer of polymerase chain reaction (PCR)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. The company offers two automated instruments platform, Amplidiag and Novodiag, which deliver rapid turnaround times ranging from 50 minutes to two hours.
The Novodiag platform combines real-time PCR and microarray capabilities to offer high-level multiplexing. Notably, the highly multiplexed assays enable clinicians to spot the person responsible for an infection quickly, accurately and efficiently.
Hologic plans to invest in assay development and expects to finance the transaction with cash on hand and borrowing on its existing line of credit.
Significance of the Acquisition
The Hologic management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenge faced in multiplexed point-of-care molecular testing. Per management, the acquisition will strengthen Hologic’s international capabilities and diagnostics businesses by expanding into the fast-growing acute care adjacency.
The acquisition will offer an exceptional new platform for growth, which will generate long-term value by allowing Hologic to tap into the acute care market, which is estimated to double over the next five years.
Industry Prospects
Per a report by Grand View Research, the global molecular diagnostics market size was valued at $36.2 billion in 2020 and is expected to reach $49.3 billion by 2028, at a CAGR of 3.9%. Rising demand for Point-of-Care testing, more need for self-testing diagnostics, and increased consumer awareness about faster diagnostics are driving the market.
Recent Notable Acquisitions
In March, Hologic acquired Diagenode -- a developer and manufacturer of molecular diagnostic assays and epigenetics products -- for nearly $159 million. The buyout strengthens Hologic’s molecular diagnostics business by expanding its international capabilities, improving regional time-to-market and offering a broader differentiated test menu.
In February, Hologic acquired Biotheranostics Inc. -- a leader in molecular oncology -- for around $230 million. The acquisition allows Hologic to tap into the rapidly-growing oncology market.
Price Performance
Shares of the company have surged 79.8% in a year’s time compared with the industry’s growth of 35.3%.
Asensus Surgical has a projected long-term earnings growth rate of 71%.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
ConforMIS has a projected long-term earnings growth rate of 42%.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Hologic (HOLX) to Buy Mobidiag, Boost Diagnostics Testing Arm
Hologic, Inc. (HOLX - Free Report) recently entered into a definitive agreement to acquire Finnish-French biotechnology company Mobidiag Oy for an enterprise value of nearly $795 million. This development is likely to strengthen Hologic’s diagnostics business and accelerate growth post-COVID.
Notably, the transaction is anticipated to close early in the fourth quarter of fiscal 2021, subject to the receipt of certain regulatory approvals and other customary closing conditions.
Financial Terms of the Deal
The transaction includes a cash payment of nearly $714 million for Mobidiag’s equity and net debt of around $81 million.
For investors’ note, Mobidiag generated revenues of $42 million (€35 million) in 2020.
Hologic expects the acquisition to prove dilutive to its adjusted earnings per share by around 10 cents in fiscal 2022, slightly dilutive in 2023, accretive thereafter.
Mobidiag at a Glance
Mobidiag is a developer and marketer of polymerase chain reaction (PCR)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. The company offers two automated instruments platform, Amplidiag and Novodiag, which deliver rapid turnaround times ranging from 50 minutes to two hours.
The Novodiag platform combines real-time PCR and microarray capabilities to offer high-level multiplexing. Notably, the highly multiplexed assays enable clinicians to spot the person responsible for an infection quickly, accurately and efficiently.
Hologic plans to invest in assay development and expects to finance the transaction with cash on hand and borrowing on its existing line of credit.
Significance of the Acquisition
The Hologic management believes that Mobidiag has created a differentiated platform that deals with many of the historical challenge faced in multiplexed point-of-care molecular testing. Per management, the acquisition will strengthen Hologic’s international capabilities and diagnostics businesses by expanding into the fast-growing acute care adjacency.
The acquisition will offer an exceptional new platform for growth, which will generate long-term value by allowing Hologic to tap into the acute care market, which is estimated to double over the next five years.
Industry Prospects
Per a report by Grand View Research, the global molecular diagnostics market size was valued at $36.2 billion in 2020 and is expected to reach $49.3 billion by 2028, at a CAGR of 3.9%. Rising demand for Point-of-Care testing, more need for self-testing diagnostics, and increased consumer awareness about faster diagnostics are driving the market.
Recent Notable Acquisitions
In March, Hologic acquired Diagenode -- a developer and manufacturer of molecular diagnostic assays and epigenetics products -- for nearly $159 million. The buyout strengthens Hologic’s molecular diagnostics business by expanding its international capabilities, improving regional time-to-market and offering a broader differentiated test menu.
In February, Hologic acquired Biotheranostics Inc. -- a leader in molecular oncology -- for around $230 million. The acquisition allows Hologic to tap into the rapidly-growing oncology market.
Price Performance
Shares of the company have surged 79.8% in a year’s time compared with the industry’s growth of 35.3%.
Zacks Rank and Other Key Picks
Currently, Hologic carries a Zacks Rank #2 (Buy).
Other similar-ranked stocks from the broader medical space include Asensus Surgical, Inc. , Cantel Medical Corp. and ConforMIS, Inc. , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Asensus Surgical has a projected long-term earnings growth rate of 71%.
Cantel Medical has an estimated long-term earnings growth rate of 19%.
ConforMIS has a projected long-term earnings growth rate of 42%.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>